Navigation Links
Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Dipexium Pharmaceuticals today provided an update of its development activities and announced its milestones to be achieved during 2011. Management announced that it has completed successfully initial six-months' stability testing on the original formulation of Locilex™ (pexiganan acetate 1% cream) and has moved on with its manufacturers to expand the batch size for clinical and commercial production.  In addition, the Company has received formal and clear clinical guidance from the FDA to support its Phase 3 clinical and regulatory pathway to resubmission of its new drug application (NDA) for Locilex™ in the U.S.

The Company also announced that its critical milestones for 2011 include the following:

  • Manufacturing:  The Company anticipates completing the work required to support its chemistry, manufacturing and controls (CMC) meeting with FDA in May 2011;
  • CMC Meeting:  The Company anticipates convening a CMC meeting with FDA in August 2011 to finalize the Company's manufacturing plans and use of product supply in the upcoming Phase 3 program;
  • Special Protocol Assessment (SPA) Filing:  The Company intends to file for a SPA designation in September 2011 shortly after the tentatively planned scheduled CMC meeting.

"Successfully achieving these value-inflection points should significantly reduce the risk associated with completing the drug development of Locilex™ and position the Company for further financing or other strategic alternatives," stated David P. Luci, Co-Founder & Managing Partner.

About Dipexium:

Dipexium Pharmaceuticals, LLC is an emerging biopharmaceutical company initially formed to complete the development and initiate the commercialization of Locilex™ (pexiganan acetate 1% cream), a novel, small peptide anti-infective agent. Locilex™ is formulated
'/>"/>

SOURCE Dipexium Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
2. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
3. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
4. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
5. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
6. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
7. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
8. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
9. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
(Date:3/27/2015)... , March 27, 2015 The International ... of myeloma patients while working toward prevention and a ... (D-NY) for introducing a federal resolution (H. Res. 174) ... 2015 as "National Multiple Myeloma Awareness Month." ... myeloma worldwide, and more than 110,000 new cases are ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... 21 /PRNewswire/ Terumo Heart, Inc. today,announced the discharge of ... Assist System (LVAS). The patient was,discharged home on August ... after receiving the device., The patient is a ... heart failure for nearly 20 years. He is the ...
... have a study,that is falling behind with recruitment? Have ... media but still have not seen the,desired results? Perhaps ... to help,your sites navigate the world of media placements ... Argonauta Assist(TM) service," says Ms. Ann Kottcamp,President of Argonauta ...
Cached Medicine Technology:Discharge of First U.S. DuraHeart(TM) Patient 2Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts 2
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... March 28, 2015 Aureus Medical ... staffing, including physical therapy jobs, has announced that ... Ohio Physical Therapy Association Annual Conference to be ... Downtown Hotel in Columbus, OH. , The ... and exhibits with products and services. , ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... study finds that people who receive higher disability ratings ... the long term than those who get lower ratings.// ... first to examine the relationship between Workers’ Compensation settlements ... which reinforces previous research showing ‘blacks receive less treatment ...
... suggests that patients who receive transfusions during heart bypass ... infections, and dying, after their operation. ,In ... medical mystery: why women bypass patients are more likely ... after surgery. Women are more likely to receive blood ...
... Kidney stones in children—considered all but a medical aberration ... a growing and disturbing trend that has pediatricians at ... sounding the alarm. ,While doctors have yet to ... behind it—better detection devices probably play some role—pediatricians agree ...
... strategy to combat malaria is abuzz, and the main action ... // ,The researchers from the National Institutes of Health ... mice, instigated them to produce antibodies against the parasite, Plasmodium ... of the mice, gain access into the mosquito’s body, through ...
... expressed their shock and disappointment on hearing the news ... //sentences on five Bulgarian nurses and one Palestinian doctor ... ,George Bush has expressed his "disappointment" to ... Bulgaria's attempts to strive for the release of the ...
... Muir Beach, CA, was living day-to-day, extremely ill, with ... dependent// on kidney dialysis. She needed a kidney transplant ... her doctors believed that a transplant was not possible ... specialized type of anti-rejection therapy pioneered at Cedars-Sinai Medical ...
Cached Medicine News:Health News:Is Workers’ Comp. Settlements for Back Pain Fair 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3Health News:Kidney Stones Occurring More Often in Children 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 3Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 4
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: